tiprankstipranks
Advertisement
Advertisement

BLTE Stock Latest News

Belite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant
The FlyBelite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant
2d ago
BLTE
Belite Bio price target lowered to $215 from $223 at Mizuho
PremiumThe Fly
Belite Bio price target lowered to $215 from $223 at Mizuho
21d ago
BLTE
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target
PremiumRatings
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target
27d ago
BLTE
Belite Bio Ramps Toward Tinlarebant Launch
PremiumCompany Announcements
Belite Bio Ramps Toward Tinlarebant Launch
27d ago
BLTE
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base
PremiumCompany Announcements
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base
28d ago
6K
BLTE
Belite Bio reports Q1 non-GAAP EPS (34c), consensus (64c)
PremiumThe FlyBelite Bio reports Q1 non-GAAP EPS (34c), consensus (64c)
28d ago
BLTE
Belite Bio receives orphan drug status for tinlarebant in Switzerland
Premium
The Fly
Belite Bio receives orphan drug status for tinlarebant in Switzerland
29d ago
BLTE
Is BLTE a Buy, Before Earnings?
Premium
Pre-Earnings
Is BLTE a Buy, Before Earnings?
1M ago
BLTE
Belite Bio management to meet wit Cantor
PremiumThe Fly
Belite Bio management to meet wit Cantor
2M ago
BLTE
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks
PremiumRatings
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks
2M ago
BLTE
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease
PremiumCompany Announcements
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease
2M ago
6K
BLTE
Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant
PremiumThe Fly
Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant
2M ago
BLTE
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
PremiumCompany AnnouncementsBelite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
3M ago
BLTE
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
Premium
Company Announcements
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
3M ago
6K
BLTE
Belite Bio Eyes 2027 Launch After Pivotal Win
Premium
Company Announcements
Belite Bio Eyes 2027 Launch After Pivotal Win
3M ago
BLTE
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
PremiumThe Fly
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
4M ago
BLTE
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
PremiumThe Fly
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
4M ago
BLTE
Belite Bio price target raised to $217 from $187 at Benchmark
PremiumThe Fly
Belite Bio price target raised to $217 from $187 at Benchmark
4M ago
BLTE
Belite Bio price target raised to $201 from $191 at Morgan Stanley
PremiumThe Fly
Belite Bio price target raised to $201 from $191 at Morgan Stanley
4M ago
BLTE
Belite Bio price target raised to $200 from $195 at BofA
PremiumThe FlyBelite Bio price target raised to $200 from $195 at BofA
4M ago
BLTE
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
Premium
Ratings
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
4M ago
BLTE
Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
Premium
The Fly
Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
4M ago
GD
VG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >